Posts

Showing posts with the label total yeast and mold count

Objectionable Microorganisms Beyond USP: FDA Expectations, Risk Assessment & GMP Guide (2026)

Image
PHARMACEUTICAL MICROBIOLOGY | GMP | FDA REGULATORY GUIDE 2026 Objectionable Microorganisms Beyond USP <62>: FDA Expectations, Risk Assessment & GMP Guide (2026) A practical scientific guide to identifying, evaluating and controlling unlisted opportunistic pathogens and recurring environmental flora in pharmaceutical manufacturing. INSPECTION WARNING: YOUR MICROBIAL COUNT MEETS SPECIFICATION. YOUR USP <62> TEST RESULTS ARE NEGATIVE. BUT FDA STILL QUESTIONS YOUR BATCH RELEASE. WHY? Because compliance with a numerical microbial limit does not automatically demonstrate that an identified microorganism is acceptable for the intended pharmaceutical product. Pharmaceutical microbiologists frequently face a difficult question: What should happen when an organism is recovered from a nonsterile pharmaceutical product, raw material, purified water system or manufacturing environment, but the organism is not specifica...

Microbial Limit Test (MLT): Procedure, USP & IP 2.2.9, Limits

Microbial Limit Test (MLT): Procedure, USP & IP 2.2.9, Limits Microbial Limit Testing (MLT) is a fundamental quality control test in pharmaceutical microbiology that determines the number and types of microorganisms present in non-sterile products . It ensures that microbial contamination remains within acceptable limits and that the product is safe for patient use. 🔬 What is Microbial Limit Testing? Microbial Limit Testing evaluates the bioburden (microbial load) of pharmaceutical products such as tablets, syrups, ointments, and creams. It checks for both: Quantitative limits – total number of viable microorganisms (bacteria, yeast, and mold) Qualitative limits – absence of specified pathogenic microorganisms (e.g., Escherichia coli , Salmonella , Staphylococcus aureus ) 📘 Reference Guidelines: United States Pharmacopeia ( USP <61> & <62> ) European Pharmacopoeia ( EP 2.6.12 & 2.6.13 ) Indian Pharmacopoeia ( IP 2.2.9 & 2.2...

Popular posts from this blog

TNTC in Microbiology: Meaning, Full Form, Calculation & TFTC Explained

NVPC in Pharma: Full Form, Limits, Guidelines & Non-Viable Particle Count

USP 41; Balances Explained (2026): Measurement Uncertainty, Minimum Weight, Audit Readiness; Why USP Revised the Rule